A major barrier to hepatitis C treatment uptake and delivery is the association of this therapy with frequent, and at times serious, adverse effects. This Review article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.
- Mark S. Sulkowski
- Curtis Cooper
- Olav Dalgard
